Site-specific recombinase based method for producing adenoviral vectors
CA 2460157 A1 · Owner: Clontech Laboratories, Inc. · Inventors: Quinn, Thomas Patrick; Farmer, Andrew Alan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Site-specific recombinase based methods for making a recombinant adenoviral genome, as well as kits for practicing the same and the recombinant adenovirus vectors produced thereby, are provided. In the subject methods the subject , genomes are prepared from donor and acceptor vectors that each include at least one site recombinase recognition site where in certain preferred , embodiments one of the donor and acceptor vectors includes a single recombinase recognition site while the other includes two recombinase recognition sites. The acceptor vector includes an adenoviral genome having an E region deletion. The donor vector includes an insertion nucleic acid. In the subject methods, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 17, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 17, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 17, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.